Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in human study of CK-4015089

Next Previous
X
Search
Trial Profile

First in human study of CK-4015089

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CK 4015089 (Primary)
  • Indications Muscular dystrophies
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 13 Nov 2024 New trial record
    • 11 Nov 2024 According to Cytokinetics media release, company announced that first participants have been dosed in a Phase 1 study of CK-4015089 (CK-089) in healthy human participants.
    • 06 Nov 2024 According to Cytokinetics media release, company expect to advance CK-4015089 with potential therapeutic application to a specific type of muscular dystrophy, into a first-in-human Phase 1 study in Q4 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top